Prescribing information

 

   

Durable relapse-free survival at five years1,2

TAFINLAR (dabrafenib) in combination with MEKINIST (trametinib) is indicated in adults for the adjuvant treatment of Stage III BRAF V600-positive melanoma, following complete resection.3,4

Landmark data demonstrate that the combination of TAFINLAR + MEKINIST offers patients a chance for DURABLE relapse-free survival at five years1,2


Please select an option below to find out more about the efficacy and safety profile of TAFINLAR + MEKINIST from the Phase III COMBI-AD clinical trial, or to discover more about patient management.

References

  1. Long GV, et al. N Engl J Med 2017;377:1813–1823.
  2. Dummer R, et al. N Engl J Med 2020;DOI:10.1056/NEJMoa2005493.
  3. TAFINLAR (dabrafenib) Summary of Product Characteristics.
  4. MEKINIST (trametinib) Summary of Product Characteristics.
UK | December 2020 | 100874
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]